首页> 外文期刊>Chinese Medicine >The development of an herbal material quality control strategy considering the effects of manufacturing processes
【24h】

The development of an herbal material quality control strategy considering the effects of manufacturing processes

机译:考虑制造过程影响的草药材料质量控制策略的开发

获取原文
           

摘要

Quality by design (QbD) is an advanced drug quality control concept that has been gradually implemented in the optimization of manufacturing processes of Chinese medicines. However, the variation of Chinese medicinal material quality has rarely been considered in published works. Because manufacturing processes may lower the variation introduced through different batches of materials, a material quality control strategy should be developed considering the influences of manufacturing processes. In this work, the processes of extraction, concentration, water precipitation, and chromatography for notoginseng total saponin (NTS) production were investigated while considering Panax notoginseng quality variation as a sample. Ten process parameters were studied simultaneously using a definitive screening design. After the process critical quality attributes (CQAs) were determined, critical process parameters (CPPs) and critical material attributes (CMAs) were identified simultaneously. Then, models utilizing the CMAs, CPPs, and process CQAs were developed. The design space was then calculated using a Monte Carlo simulation method with an acceptable probability of 0.90. A material quality control strategy considering the influences of manufacturing processes was proposed. The ginsenoside Rd purity and total saponin purity in the eluate were identified as process CQAs. The ethanol solution concentration used for extraction, the ethanol solution concentration used for elution, and elution time were identified as CPPs. The extractable dry matter content of Panax notoginseng was one of the CMAs. The extractable contents of notoginsenoside R1, ginsenoside Rg1, ginsenoside Rb1, and ginsenoside Rd were the other CMAs. The inequalities implemented to discriminate the high quality and low quality of Panax notoginseng were developed according to the NTS standard of the Xuesaitong injection. Low quality Panax notoginseng should not be released for NTS production. High quality Panax notoginseng can be treated with feasible manufacturing processing parameters. Verification experiments were carried out successfully for 2 batches of high quality Panax notoginseng. In this work, a quality control strategy for herbal materials was developed considering the matching of process characteristics and material quality attributes. This strategy is promising for application to other Chinese medicines.
机译:设计质量(QbD)是一种先进的药品质量控制概念,已在优化中药制造工艺中逐步实施。但是,在出版的著作中很少考虑中药材质量的变化。由于制造工艺可以降低通过不同批次的材料引入的变化,因此应考虑制造工艺的影响来制定材料质量控制策略。在这项工作中,研究了三七总皂苷(NTAX)生产中三七总皂苷(NTS)的提取,浓缩,水沉淀和色谱分离过程。使用确定的筛选设计同时研究了十个工艺参数。确定过程关键质量属性(CQA)后,同时确定关键过程参数(CPPs)和关键材料属性(CMA)。然后,开发了利用CMA,CPP和过程CQA的模型。然后使用蒙特卡罗模拟方法以0.90的可接受概率计算设计空间。提出了一种考虑制造过程影响的材料质量控制策略。洗脱液中的人参皂苷Rd纯度和总皂苷纯度确定为过程CQA。将用于提取的乙醇溶液浓度,用于洗脱的乙醇溶液浓度和洗脱时间鉴定为CPP。三七的可提取干物质含量是CMA之一。三七皂苷R1,人参皂苷Rg1,人参皂苷Rb1和人参皂苷Rd的可提取成分是其他CMA。根据血塞通注射液的NTS标准,开发了用于区分三七高品质和低品质的不平等现象。低质量三七不能用于NTS生产。高质量的三七可以用可行的制造工艺参数进行处理。对两批优质三七进行了验证实验。在这项工作中,考虑到过程特性和材料质量属性的匹配,制定了草药材料的质量控制策略。该策略有望应用于其他中药。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号